Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board

Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development

Recent advances in AI for antimicrobial resistance (AMR) prevention and control

antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices